NASDAQ · Financial Statements

Anika Therapeutics Inc. (ANIK) Financial Statements

$21.42 NASDAQ: ANIK Market Cap $286.66M

Anika Therapeutics Inc. most recently reported annual revenue of $113.0M, a net loss of $11.0M. Revenue declined at an average annual rate of 2.8% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Anika Therapeutics Inc.: Revenue rose from $103.0M in 2016 to $113.0M in 2025, a change of +9.7% over 9 years; net profit was positive in 5 of 10 reported years; operating margin moved from 49.0% to -9.8%, a shift of -58.8 percentage points; the most recent year shows a net loss of $11.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$103.0M$113.0M$106.0M$115.0M$130.0M$148.0M$114.0M$121.0M$120.0M$113.0M
Operating Expenses$53.0M$68.0M$84.0M$80.0M$159.0M$145.0M$110.0M$120.0M$125.0M$124.0M
Operating Profit$51.0M$46.0M$22.0M$34.0M$-28.0M$3.0M$4.0M$1.0M$-5.0M$-11.0M
Operating Margin49.0%40.3%20.6%29.9%-21.7%1.8%3.2%0.7%-4.3%-9.8%
Other Income$0$0$1.0M$2.0M$0$0$1.0M$2.0M$2.0M$2.0M
Interest$0$0$0$0$1.0M$0$0$0$0$0
Depreciation$4.0M$4.0M$6.0M$6.0M$13.0M$14.0M$14.0M$14.0M$8.0M$6.0M
Profit Before Tax$51.0M$46.0M$23.0M$36.0M$-29.0M$2.0M$4.0M$3.0M$-3.0M$-9.0M
Tax$36.0M$31.1M$19.3M$24.7M$16.2M$-70.3M$49.1M$209.0M$-219.4M$-7.2M
Net Profit$33.0M$32.0M$19.0M$27.0M$-24.0M$4.0M$-15.0M$-83.0M$-56.0M$-11.0M
EPS$2.15$2.11$1.27$1.89$-1.69$0.28$-1.02$-5.64$-3.83$-0.76
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$41.0M$43.0M$41.0M$31.0M$39.0M$-1.0M$26.0M$28.0M$28.0M$31.0M$30.0M$33.0M
Operating Expenses$49.0M$107.0M$46.0M$33.0M$67.0M$-29.0M$30.0M$32.0M$31.0M$30.0M$35.0M$30.0M
Operating Profit$-8.0M$-64.0M$-5.0M$-2.0M$-28.0M$28.0M$-4.0M$-4.0M$-3.0M$1.0M$-5.0M$3.0M
Operating Margin-18.5%-148.4%-12.5%-5.9%-72.3%-2156.4%-16.4%-14.8%-11.6%2.1%-18.5%9.1%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-7.0M$-63.0M$-4.0M$-1.0M$-28.0M$29.0M$-4.0M$-4.0M$-2.0M$1.0M$-5.0M$3.0M
Tax$6.6M$320,000$-960,000$-109.1M$-8.4M$10.1M$-2.3M$-17.2M$-42.0M$-135.7M$-4.9M$2.1M
Net Profit$-7.0M$-63.0M$-5.0M$0$-30.0M$-22.0M$-5.0M$-4.0M$-2.0M$0$-5.0M$3.0M
EPS$-0.45$-4.30$-0.31$-0.01$-2.03$-1.50$-0.34$-0.28$-0.16$0.02$-0.37$0.24

Over the 10 years reported for Anika Therapeutics Inc., cash stood at $57.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 4.68 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$240.0M$283.0M$279.0M$331.0M$366.0M$348.0M$349.0M$271.0M$203.0M$190.0M
Current Assets$170.0M$206.0M$203.0M$234.0M$177.0M$169.0M$170.0M$163.0M$114.0M$103.0M
Cash$104.0M$133.0M$89.0M$157.0M$96.0M$94.0M$86.0M$69.0M$56.0M$57.0M
Inventory$16.0M$22.0M$21.0M$22.0M$46.0M$36.0M$40.0M$24.0M$24.0M$19.0M
Receivables$28.0M$24.0M$21.0M$23.0M$24.0M$30.0M$35.0M$26.0M$24.0M$24.0M
Fixed Assets$52.0M$56.0M$54.0M$74.0M$73.0M$69.0M$79.0M$65.0M$65.0M$66.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$21.0M$19.0M$63.0M$27.0M$3.0M$0$0$0$0$0
Other Assets$7.0M$8.0M$8.0M$8.0M$8.0M$8.0M$7.0M$8.0M$7.0M$8.0M
Total Liabilities$17.0M$19.0M$15.0M$42.0M$93.0M$60.0M$64.0M$58.0M$49.0M$47.0M
Current Liabilities$9.0M$13.0M$11.0M$16.0M$37.0M$30.0M$28.0M$31.0M$23.0M$22.0M
Borrowings$0$0$0$23.0M$22.0M$21.0M$31.0M$28.0M$26.0M$26.0M
Other Liabilities$17.0M$19.0M$15.0M$20.0M$71.0M$39.0M$33.0M$31.0M$23.0M$21.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$223.0M$263.0M$264.0M$288.0M$272.0M$287.0M$286.0M$212.0M$154.0M$143.0M

For Anika Therapeutics Inc., operating cash flow was positive in 9 of 10 reported years; free cash flow in the latest year was $4.0M; free cash flow was positive in 7 of 10 years; financing activities used $11.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$24.0M$41.0M$35.0M$37.0M$13.0M$8.0M$4.0M$-2.0M$5.0M$11.0M
Investing Cash Flow$-14.0M$-25.0M$-101.0M$37.0M$-73.0M$-8.0M$-15.0M$-11.0M$-16.0M$-7.0M
Financing Cash Flow$-23.0M$0$-29.0M$-8.0M$-5.0M$-8.0M$-5.0M$-6.0M$-13.0M$-11.0M
Net Cash Flow$-6.0M$29.0M$-44.0M$68.0M$-62.0M$-1.0M$-8.0M$-13.0M$-16.0M$0
Free Cash Flow$10.0M$32.0M$30.0M$34.0M$11.0M$3.0M$-3.0M$-7.0M$-2.0M$4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.25
EV / EBITDA88.52
FCF Yield0.22%
Quick Ratio3.19
Interest Coverage—
Return 1Y34.61%
Return 3Y-37.77%
Return 5Y-61.94%

Anika Therapeutics Inc. (ANIK) financials — frequently asked questions

What is Anika Therapeutics Inc.'s annual revenue?

Anika Therapeutics Inc. (ANIK) reported annual revenue of $113.0M in its most recent fiscal year.

What is Anika Therapeutics Inc.'s net profit?

Anika Therapeutics Inc. (ANIK) reported a net loss of $11.0M in its most recent fiscal year.

What is ANIK EV/EBITDA?

Anika Therapeutics Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 88.52.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
ANIK Overview ANIK Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.